Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 92Completed 83Terminated 61Active not recruiting 49Unknown 37Withdrawn 23Not yet recruiting 17Suspended 2Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Recurrence 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

toripalimab 1tislelizumab 1pembrolizumab 1ibrutinib 1fludarabine 1dynorphin-converting endopeptidase 1Spinal Puncture 1Propranolol 1Positron-Emission Tomography 1Nivolumab 1Magnetic Resonance Imaging 1JNJ-64619178 1JNJ-64264681 1Gemcitabine 1Dexamethasone 1Deoxycholic Acid 1Cyclophosphamide 1Cisplatin 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Enrolling by invitation × fludarabine × Clear all
NCT07168486 2025-09-11

CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas

University of Maryland, Baltimore

Phase 1 Enrolling by invitation
15 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡